Availability: In Stock
Average Delivery Time: 9 Days
Exp. Date: May 2024
|Ventolin Inhaler 100 mcg|
6 inhaler - 100 mcg
+ 4 free Viagra 100 mg, 3% discount for future orders
|$139.83||$23.31||$75.87||Add to cart|
|3 inhaler - 100 mcg||$75.93||$25.31||$31.92||Add to cart|
|1 inhaler - 100 mcg||$35.95||$35.95||No||Add to cart|
Selective β2-adrenoreceptor agonist. In therapeutic doses it acts on β2-adrenoreceptors of bronchial smooth muscle and produces a short-lasting (4 to 6 hours) bronchodilator effect on β2-adrenoreceptors with rapid onset of action (within 5 min) in reversible airway obstruction.
It has a pronounced bronchodilator effect, preventing or terminating bronchospasm, reduces airway resistance. Increases the vital capacity of the lungs. Increases mucociliary clearance (in chronic bronchitis up to 36%), stimulates mucus secretion, activates the functions of the intermittent epithelium.
In the recommended therapeutic doses it does not have an adverse effect on the cardiovascular system and does not cause an increase in BP. To a lesser extent, compared to the drugs of this group, it has positive chrono- and inotropic effects. Causes dilation of the coronary arteries.
It has a number of metabolic effects: decreases the concentration of potassium in plasma, affects glycogenolysis and insulin release, has hyperglycemic (especially in patients with bronchial asthma) and lipolytic effects, increases the risk of acidosis.
After inhalation administration, 10-20% of the dose of salbutamol reaches the lower respiratory tract. The remainder of the dose remains in the inhaler or is deposited in the oropharynx and then swallowed. The fraction deposited in the respiratory tract is absorbed into lung tissue and blood, but is not metabolized in the lungs.
The binding of salbutamol to plasma proteins is 10%.
When ingested into the systemic bloodstream, salbutamol undergoes hepatic metabolism and is excreted mainly by the kidneys unchanged or as phenol sulfate. The swallowed portion of the inhaled dose is absorbed from the gastrointestinal tract and undergoes significant metabolism during "first passage" through the liver, being converted into phenolic sulfate. The unchanged salbutamol and the conjugate are excreted primarily by the kidneys.
Salbutamol administered v/v has a T1/2 of 4-6 h. It is excreted partly by the kidneys and partly as a result of metabolism to inactive 4'-O-sulfate (phenol sulfate), which is also excreted mainly by the kidneys Only a small part of the administered dose of salbutamol is excreted through the intestine. Most of the dose of salbutamol administered by IV, oral or inhalation is excreted within 72 hours.
Contraindications to use
- Management of preterm birth;
- Threatened abortion;
- Hypersensitivity to the drug components or any other component of the drug.
Salbutamol should be used with caution in patients with thyrotoxicosis, tachyarrhythmia, myocarditis, cardiac defects, aortic stenosis, CHD, severe chronic heart failure, arterial hypertension, pheochromocytoma, decompensated diabetes mellitus, glaucoma.
Application during pregnancy and lactation
During pregnancy, the drug should be administered only if the expected benefits to the mother exceed the potential risk to the fetus.
During post-registration monitoring, rare cases of various malformations in children, including the formation of "wolf's mouth" and limb malformations, have been identified while taking salbutamol during pregnancy. In some of these cases, the mothers had taken several concomitant medications during pregnancy. Because of the lack of a consistent pattern of defects and the background incidence of congenital anomalies, ranging from 2 to 3%, a causal relationship with drug intake has not been established.
Salbutamol is likely to penetrate into breast milk and therefore is not recommended for breastfeeding women unless the expected benefit to the mother herself outweighs the potential risk to the baby. There are no data on whether salbutamol present in breast milk has harmful effects on the newborn.
There are no data on the effects of salbutamol on human fertility. No undesirable effects on animal fertility have been identified in preclinical studies.
Indications of Ventolin
- Management of bronchial asthma symptoms when they occur;
- prevention of bronchospasm attacks associated with exposure to an allergen or caused by physical activity;
- use as one of the components in long-term maintenance therapy of bronchial asthma.
Other chronic lung diseases with reversible airway obstruction, including COPD, chronic bronchitis, and pulmonary emphysema.
Bronchodilators should not be the sole or main component of therapy for unstable or severe bronchial asthma. If there is no response to salbutamol in patients with severe bronchial asthma, GCS therapy is recommended in order to achieve and maintain disease control. Lack of response to salbutamol therapy may indicate the need for urgent medical consultation or treatment.
Ventolin is intended to be administered by inhalation by mouth only.
An increased need for β2-adrenoreceptor agonists may be a sign of worsening bronchial asthma. In such a situation, it may be necessary to reevaluate the patient's treatment regimen with consideration of the advisability of simultaneous GCS therapy.
Since overdose may be accompanied by the development of adverse reactions, the dose or frequency of drug administration may be increased only on the doctor's recommendation.
The duration of action of salbutamol in most patients is 4 to 6 hours.
A spacer may be used in patients who have difficulty synchronizing inhalation with the use of a pressurized metered-dose aerosol inhaler.
In children and infants receiving Ventolin, the use of a pediatric spacer device with a face mask is appropriate.
To relieve an attack of bronchospasm in adults, the recommended dose is 100 or 200 mcg; in children, 100 mcg; if necessary, the dose may be increased to 200 mcg. It is not recommended to use Ventolin inhaler more than 4 times per day. The need for such frequent use of additional doses of Ventolin or a sharp increase in the dose indicates a worsening of the course of asthma.
For prevention of bronchospasm attacks, which are related to allergen exposure or caused by physical exertion, in adults - 200 micrograms 10-15 minutes before exposure to provoking factor or load; in children - 100 micrograms 10-15 minutes before exposure to provoking factor or load, if necessary, the dose can be increased to 200 micrograms.
During long-term maintenance therapy in adults - up to 200 micrograms 4 times per day, in children - up to 200 micrograms 4 times per day.
Rules of inhaler use
Checking the inhaler
Before using your inhaler for the first time or if you have not used it for a week or more, remove the cap from the mouthpiece by gently squeezing the cap at the sides, shake the inhaler well and spray the air twice to check that the inhaler works.
Using the inhaler
1. Remove the cap from the mouthpiece by gently squeezing the cap from the sides.
Inspect the mouthpiece inside and outside to make sure it is clean. 3.
Shake the inhaler well.
4. Hold the inhaler between your index finger and thumb in an upright position with the bottom up, with your thumb resting on the base under the mouthpiece.
5. Take a slow, deep exhalation, wrap your lips around the mouthpiece without clenching it with your teeth.
6. Taking the deepest possible breath through the mouth, simultaneously press the top of the inhaler to release one inhaled dose of salbutamol.
7. Hold your breath for a few seconds, take the mouthpiece out of your mouth, then slowly exhale.
8. For the second dose, holding the inhaler upright, wait about 30 seconds and then repeat steps 3-7. 3-7.
9. Close the mouthpiece tightly with the protective cap.
Do not hurry while performing stages 5, 6 and 7. Start breathing in as slowly as possible, just before pressing the valve of the inhaler. The first few times, it is advisable to practice in front of a mirror. If you see a "mist" coming out of the top of the inhaler or from the corners of the mouth, you should start again from stage 2.
If the doctor has given other instructions on how to use the inhaler, the patient should strictly follow them. If the patient has difficulty using the inhaler, he or she should contact the doctor.
Cleaning the inhaler
The inhaler should be cleaned at least once a week.
Take the metal canister out of the plastic housing and remove the mouthpiece cap. 2.
Rinse the plastic casing and the cap of the nozzle thoroughly under running warm water. 3.
3. Dry the plastic body and the mouthpiece cap completely inside and outside. Do not allow to overheat.
4. Place the metal can into the plastic casing and put the cap on the mouthpiece.
Do not immerse the metal can in water.